AI could be used to guide drug therapy for heart failureUK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who Share XAI could be used to guide drug therapy for heart failurehttps://pharmaphorum.com/news/ai-could-be-used-to-guide-drug-therapy-for-heart-failure/
Real-world study suggest AI may improve atrial fibrillation screeningAn artificial intelligence algorithm already shown to be able to detect atrial fibrillation (AF) in clinical testing has Share XReal-world study suggest AI may improve atrial fibrillation screeninghttps://pharmaphorum.com/news/real-world-study-suggest-ai-may-improve-atrial-fibrillation-screening/
FDA clears Medtronic AI algorithms for cardiac monitoringTwo artificial intelligence (AI) algorithms designed to diagnose people with heart rhythm abnormalities have been approved by the Share XFDA clears Medtronic AI algorithms for cardiac monitoringhttps://pharmaphorum.com/news/fda-clears-medtronic-ai-algorithms-for-cardiac-monitoring/
MedLumics raises €18 million for atrial fibrillation deviceMedLumics has raised another €18 million (around $22 million) to fund clinical trials of its optically-guided imaging system Share XMedLumics raises €18 million for atrial fibrillation devicehttps://pharmaphorum.com/news/medlumics-raises-e18-million-for-atrial-fibrillation-device/
iRhythm digital heart monitoring service backed by NICEA heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a Share XiRhythm digital heart monitoring service backed by NICEhttps://pharmaphorum.com/news/irhythm-digital-heart-monitoring-service-backed-by-nice/
RHYTHM AI cleared for large trial of atrial fibrillation mapping toolUK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, Share XRHYTHM AI cleared for large trial of atrial fibrillation mapping toolhttps://pharmaphorum.com/news/rhythm-ai-cleared-for-large-trial-of-atrial-fibrillation-mapping-tool/
AI study will help select AFib patients for shock treatmentA new study is trying to find out why electrical cardioversion (ECV) or shock treatment only works in Share XAI study will help select AFib patients for shock treatmenthttps://pharmaphorum.com/news/ai-study-will-help-select-afib-patients-for-shock-treatment/
AI-driven atrial fibrillation project begins after seed funding roundClinical development of an AI-driven system that identifies the sources or drivers of atrial fibrillation (AF), and could Share XAI-driven atrial fibrillation project begins after seed funding roundhttps://pharmaphorum.com/news/ai-driven-atrial-fibrillation-project-begins-after-seed-funding-round/
Lixiana hits the mark in catheter ablation trialDaiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker Share XLixiana hits the mark in catheter ablation trialhttps://pharmaphorum.com/news/lixiana-hits-the-mark-in-catheter-ablation-trial/
